Skip to main content

Breast Cancer

Breast Cancer

BYLieve Study Results Support the Use of Alpelisib Combined with Fulvestrant for Hormone Receptor–Positive, HER2-Negative, PIK3CA Mutation–Positive Advanced Breast Cancer

Breast Cancer

PALOMA-3 Trial Shows Benefits to Overall Survival as Measured by Prognostic Indicators

Breast Cancer, CDK4/6 Inhibitors, Radiation Therapy

Favorable Tolerability Profile of Sequential Radiation Therapy in Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer

Breast Cancer

Expanded Safety Analysis of the Phase 3b CompLEEment-1 Trial with Ribociclib plus Letrozole in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Breast Cancer, CDK4/6 Inhibitors

A Network Meta-Analysis of Treatment-Related Adverse Events of Various CDK4/6 Inhibitors in Metastatic Breast Cancer

Breast Cancer

Maintenance Therapy with Everolimus plus Aromatase Inhibitors in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Updated Analyses of the Phase 3 Randomized MAIN-A Trial

Breast Cancer

Patients with Metastatic Breast Cancer and the Use of Chemotherapy During End of Life

Breast Cancer

In a Real-World Setting, the RIBANNA Study Showed Diverse Population Characteristics Among Patients Who Received Ribociclib Treatment

Breast Cancer, CDK4/6 Inhibitors

Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer

Breast Cancer

Efficacy Outcomes of Platinum-Based Chemotherapy in Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Page 9 of 12
Results 81 - 90 of 116